Patents/Assignees

Ionis Pharmaceuticals, Inc.

61 patents in portfolio

US12618069utility2026
Compounds and Methods for Reducing ATXN3 Expression
0 cites
US12606826utility2026
Modulation of Transthyretin Expression
0 cites
US12600970utility2026
Compositions for Modulating C9ORF72 Expression
0 cites
US12595482utility2026
Linkage Modified Oligomeric Compounds and Uses Thereof
0 cites
US12595485utility2026
Modulation of Prekallikrein (PKK) Expression
0 cites
US12584128utility2026
Compositions for Modulating Ataxin 2 Expression
0 cites
US12529055utility2026
Methods and Compositions for Inhibiting PMP22 Expression
0 cites
US12509684utility2025
Compositions and Methods for Modulating Apolipoprotein C-III Expression
0 cites
US12502402utility2025
Compounds and Methods for Modulating GFAP
0 cites
US12496311utility2025
Methods for Safely Reducing Thrombopoietin
0 cites
US12409188utility2025
Modulators of HSD17B13 Expression
0 cites
US12384814utility2025
Compounds and Methods for Reducing App Expression
0 cites
US12350285utility2025
Compounds and Methods for Reducing ATXN3 Expression
0 cites
US12343357utility2025
Compositions and Methods for Modulating MECP2 Expression
0 cites
US12297431utility2025
Modulation of Huntingtin Expression
0 cites
US12291709utility2025
Compositions and Methods for Modulating Apolipoprotein (a) Expression
0 cites
US12281305utility2025
Compounds and Methods for Reducing Prion Expression
0 cites
US12275940utility2025
Conjugated Antisense Compounds and Their Use
0 cites
US12241067utility2025
Compounds and Methods for Reducing LRRK2 Expression
0 cites
US12234447utility2025
Modified Compounds and Uses Thereof
0 cites

Page 1 of 4Next →